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Abstract Heart failure (HF) is characterized by molecu-
lar and cellular defects which jointly contribute to
decreased cardiac pump function. During the development
of the initial cardiac damage which leads to HF, adaptive
responses activate physiological countermeasures to over-
come depressed cardiac function and to maintain blood
supply to vital organs in demand of nutrients. However,
during the chronic course of most HF syndromes, these
compensatory mechanisms are sustained beyond months
and contribute to progressive maladaptive remodeling of
the heart which is associated with a worse outcome. Of
pathophysiological signiﬁcance are mechanisms which
directly control cardiac contractile function including ion-
and receptor-mediated intracellular signaling pathways.
Importantly, signaling cascades of stress adaptation such as
intracellular calcium (Ca
2?) and 30-50-cyclic adenosine
monophosphate (cAMP) become dysregulated in HF
directly contributing to adverse cardiac remodeling and
depression of systolic and diastolic function. Here, we
provide an update about Ca
2? and cAMP dependent
signaling changes in HF, how these changes affect cardiac
function, and novel therapeutic strategies which directly
address the signaling defects.
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Congestive heart failure (HF) is a condition in which heart
function is insufﬁcient to supply the organs with enough
blood nutrients. The consequence is a progressive cascade
of changes that lead to fatigue, shortness of breath and,
ultimately, death. Much progress has been made in
understanding the molecular and cellular processes that
contribute to HF. Despite these insights and modern
treatment options, chronic HF remains a major cause of
illness and death and generally has a poor prognosis.
Because HF is more common with increasing age, the
number of affected individuals is rising rapidly with the
ageing population. Thus, new treatments directed at critical
disease mechanisms are needed to halt and reverse the
devastating consequences of this disease.
Here, we focus on chronic HF and our understanding of
molecular disease mechanisms related to Ca
2? metabolism.
Many insights into HF stem from the elucidation of intra-
cellular signaling pathways that mediate cardiac perfor-
mance as well as contribute to cardiac dysregulation under
disease conditions. The clinically critical transition occurs
when the heart can no longer provide adequate blood ﬂow
and/or pressure to meet the body’s demands. Consequently,
physiological countermeasures include the stimulation of
neurohormonal outﬂow and the activation of intracellular
signaling cascades. These acute responses may initially
offset reduced cardiac performance. However, sustained
stimulation of the heart by cellular stress signaling cas-
cades ultimately increases the likelihood of organ failure
and contributes to a worse prognosis.
Cardiac remodeling and changes in intracellular
signaling
HF is characterized by chronic activation of neuro-hor-
monal pathways representing a compensatory response to
overcome depressed cardiac function. However, over
weeks to months, a chronic hyperadrenergic state ensues
with elevated plasma catecholamine levels, which con-
tribute to maladaptive cardiac chamber remodeling, pro-
gressive deterioration of pump function, and deadly
arrhythmias. Due to the chronic hyperadrenergic state,
desensitization of b-adrenoreceptors (b-ARs) and reduced
global intracellular cAMP synthesis occur in the failing
heart [1–3]. However, stimulation of b-ARs and other
signaling pathways is maintained and continues to affect
the remodeled cells and proteins.
A broad range of molecular pathways are involved in the
development of HF, and there is likely to be substantial
overlap between these pathways. Typically, cell-surface
receptors are activated by ligands leading to the activation
of stress-response protein kinases and phosphatases such as
cAMP-dependent protein kinase A (PKA), protein kinase C
(PKC), protein kinase D (PKD), mitogen activated kinases
(MAPKs), Ca
2? calmodulin-dependent kinase II (CaMKII),
and calcineurin. Chronic activation of these stress pathways
and their cellular effectors including transcription factors,
which target multiple genes, result in changes in cellular
structure, function, and overall regulation of the heart,
collectively referred to as cardiac remodeling. Additionally,
an imbalance between cell survival and cell death pathways
results in a low rate of cardiomyocyte apoptosis which may
contribute to cell loss in HF [4, 5]. A different form of cell
death, necrosis, may contribute to HF, for example through
mitochondrial damage mediated by increased cytosolic
Ca
2? concentrations in cardiomyocytes.
HF causes changes in intracellular calcium signals
HF is a syndrome which results from different insults,
typically following myocardial infarction (MI), viral
myocarditis, toxic cardiomyopathy, or other less frequent
causes such as genetic defects. However, following chronic
remodeling of the heart, cardiac phenotypes occurring from
different causes show important similarities, including
depressed intracellular Ca
2? metabolism.
Ca
2? is the central regulator of excitation-contraction
(EC) coupling, which controls muscle contraction during
each heartbeat. EC coupling is activated by an incoming
action potential wavefront and the subsequent opening of
voltage-dependent L-type Ca
2? channels (CaV1.2). A rel-
atively small Ca
2? inﬂux current (ICa) triggers a quantita-
tively larger intracellular Ca
2? release from sarcoplasmic
reticulum (SR) Ca
2? stores through ryanodine receptor
(RyR2) Ca
2? release channels by the process of Ca
2?
induced Ca
2? release (CICR) (Fig. 1a). CICR is followed
by re-uptake of Ca
2? into the SR by Ca
2? pumps (SERCA2)
and removal of Ca
2? from the cytosol by the Na
?/Ca
2?
exchanger (NCX) (Fig. 1a). The activity of SERCA2 is
regulated by phospholamban (PLN). Unphosphorylated
PLN inhibits SERCA2 activity, and phosphorylation by
PKA and/or CaMKII increases SR Ca
2? uptake. Similarly,
RyR2 phosphorylation by PKA and/or CaMKII increases
SR Ca
2? release [6, 7]. Within the approximately 12 nm
wide compartment between the plasma membrane and the
terminal SR membrane (junctional SR) where SR Ca
2?
release occurs, CICR is organized within Ca
2? release units
representing functional microdomains betweenT-tubuli and
the terminal SR (junctional subspace). Strikingly, all com-
ponents essential for CICR, including the SR Ca
2? release
microdomain, the Ca
2? storage organelles, and the Ca
2?
transport proteins themselves (Table 1), become signiﬁ-
cantly altered during remodeling of the failing heart [8].
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123Milestones toward imaging of intracellular calcium
metabolism
The study of intracellular Ca
2? concentration, [Ca
2?]i,i n
heart function requires to monitor the dynamics of [Ca
2?]i
in living cells. However, the free [Ca
2?]i is heterogeneous
even in resting cells and ranges from nanomolar to
micromolar concentrations in the cytoplasm and SR Ca
2?
stores, respectively [9]. During electrical cell activation or
stimulation by hormone receptors, the resultant changes in
the cytoplasmic and organellar Ca
2? concentrations occur
as spatially and temporally deﬁned patterns within cellular
microdomains [10]. Thus, understanding of changes in
Ca
2? signaling during HF has been largely dependent on
methods to monitor Ca
2? concentrations in living cells.
Ca
2? indicators form selective and reversible complexes
with free Ca
2? ions. The physicochemical differences of
the free and bound indicator allow for the ﬂuorescence
detection of changes in D[Ca
2?]i usually by the absorbance
and/or emission of light [11]. Thus, the concentration of
free Ca
2? is measured indirectly by monitoring the amount
of the free versus the Ca
2? complexed indicator. The
chemiluminescent photoprotein aequorin puriﬁed from
Fig. 1 a Physiology of excitation-contraction (EC) coupling. An
incoming action potential (AP) rapidly depolarizes the cell membrane
potential (Vm) in phase 0 through opening of voltage-dependent Na
?
channels (NaV1.5). Subsequently, EC coupling is initiated through the
opening of voltage-dependent L-type Ca
2? channels (CaV1.2) and the
plasma membrane Ca
2? inﬂux current (ICa). ICa activates ryanodine
receptors (RyR2s) and intracellular Ca
2? release from sarcoplasmic
reticulum (SR) stores, also known as Ca
2? induced Ca
2? release
(CICR). CICR is followed by extrusion of Ca
2? from the cytosol into
the SR by Ca
2? pumps (SERCA2) and to the extracellular compart-
ment by the Na
?/Ca
2? exchanger (NCX) operating in its forward
mode (3 Na
? in for each Ca
2? out), which creates an electrogenic
inward current. SR Ca
2? leak is inhibited by the calstabin2 (Cab2)
subunit which stabilizes the RyR2 closed state. The SERCA2 pump
rate is inhibited by the phospholamban (PLN) subunit in its
dephosphorylated state. Ca
2? release and uptake occur cyclically
during each heart beat and represent 60–90% of Ca
2? signaling
during EC coupling depending on the species studied. b EC coupling
abnormalities in CPVT. RyR2 missense mutations signiﬁcantly
increase the propensity for intracellular Ca
2? leak in resting
cardiomyocytes (during diastole) with ﬁlled SR Ca
2? stores. Stim-
ulation of b-adrenergic receptors (b-ARs) during stress adaptation
results in RyR2 and PLN phosphorylation by PKA (indicated by  )
which increases SR Ca
2? release and uptake, respectively. However,
RyR2 mutations (as indicated by green star) in the PKA phosphor-
ylated Ca
2? release channel lead to partial calstabin2 depletion, a
signiﬁcant gain-of-function defect of RyR2, and intracellular Ca
2?
leak. RyR2 Ca
2? leak activates depolarizing transient inward currents
(ITI) supposedly through abnormal forward mode NCX activity. If ITI
currents reach a critical threshold of membrane potential instability in
phase 4 of the cardiac AP, Na
? channels are activated leading to
delayed after depolarizations (DADs) which underly triggered
activity. c EC coupling abnormalities in HF. HF is a chronic
hyperadrenergic state which results in downregulation of b-AR
signaling and reduced intracellular cAMP synthesis. However,
maintained hyperadrenergic stimulation of b-ARs during HF results
in chronic RyR2 PKA hyperphosphorylation (indicated by large  ),
depletion of the stabilizing calstabin2 subunits as well as other
components of the channel complex including phosphodiesterase 4D3
(PDE4D3). PDE4D3 depletion causes a chronically reduced cAMP
hydrolysis in the channel complex and contributes to RyR2 PKA
hyperphosphorylation induced intracellular Ca
2? leak. On the other
hand, PLN is chronically PKA hypophosphorylated (indicated by
small  ) creating constitutively inhibited state of SERCA2 and
reduced SR Ca
2? uptake. Additionally, NCX expression is signif-
icantly increased leading to abnormally increased Ca
2? extrusion to
the extracellular side and depletion of intracellular Ca
2? stores.
Despite Ca
2? store depletion, DADs and triggered activity are
frequent in HF possibly due to increased SR Ca
2? leak and
proarrhythmogenic inward NCX and late INa,L currents
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123jellyﬁsh can be microinjected into tissues or cells and
applied as a Ca
2? indicator [12]. Moreover, recombinant
aequorin can be targeted to speciﬁc subcellular compart-
ments through signal sequences [13]. However, recombi-
nant aequorin emits a relatively small signal upon Ca
2?
binding which compromises the measurement of Ca
2?
concentrations in smaller cells at the cost of low time
resolution [14]. Tsien and colleagues synthesized the ﬁrst,
rationally designed, ﬂuorescent Ca
2? indicator for intra-
cellular use based on the Ca
2?-chelator EGTA [15]. The
widespread and successful use of ﬂuorescent polycarbox-
ylate dyes started with the introduction of lipophilic acet-
oxymethyl (AM) ester derivatives allowing efﬁcient and
stable indicator loading of living cells without potentially
damaging pipette injection techniques [16].
Global intracellular calcium abnormalities in heart
failure
Pioneering studies used injection of the aequorin Ca
2?
sensor into physiologically contracting muscle preparations
from explanted human hearts. Aequorin loaded muscles
from failing hearts showed a reduced capacity to restore
nanomolar resting Ca
2? levels during diastole in conjunc-
tion with depressed muscle contraction and relaxation [17].
Different from healthy heart muscle and pronounced at
faster rates, the aequorin injected failing heart muscle
showed a reduced amplitude of the intracellular Ca
2?
transient (D[Ca
2?]i) together with diminished force pro-
duction [18]. Additionally, myothermal measurements in
isolated muscle strip preparations from failing and non-
failing human hearts showed that the thermal equivalent of
total Ca
2? cycling is reduced signiﬁcantly in HF [19]. The
rate of heat production was signiﬁcantly reduced indicating
reduced SR Ca
2? uptake [19].
Consistent with multicellular muscle preparations, dis-
sociated single cardiomyocytes from failing human hearts
displayed a prolonged relaxation, depressed systolic con-
traction, and elevated diastolic tension [20]. Contractile
dysfunction of failing cardiomyocytes occurred in conjunc-
tion with abnormal [Ca
2?]i metabolism including reduced
SRCa
2?release,elevatedresting[Ca
2?]i,andareducedrate
ofCa
2?removal[21,22].ForlatestageHFitisnowaccepted
that cardiomyocytes and/or muscle preparations from ex-
planted patient or animal hearts exhibit a reduced D[Ca
2?]i
amplitude and a slowed decay of the global intracellular
Ca
2? transient [17, 23–25]. Thus, depressed contractility in
HF appears to be associated with cellular signaling abnor-
malitiesattheleveloftheglobalintracellularCa
2?transient.
Notably, the combination of an abnormal intracellular
Ca
2? transient together with depressed contractile function
all occur from quite different forms of cardiac insults. Such
phenotypic changes have been documented in dilated
human cardiomyopathy [23, 26], hypertension induced
hypertrophy HF in salt-sensitive rats [24], rats with
Table 1 Major calcium
handling abnormalities in the
failing heart
ARVC2 arrhythmogenic right
ventricular cardiomyopathy
type 2, AVND atrioventricular
node dysfunction, CPVT
catecholaminergic polymorphic
ventricular tachycardia, SSS
sick sinus node, n/a not
available
Gene Physiological function Pathophysiology in HF Genetic syndromes
NCX1,
SLC8A1
Na
?/Ca
2? exchange INCX gain-of-function n/a
Forward mode Contractile dysfunction
Reverse mode Pro-arrhythmogenic
RyR2 Ryanodine receptor isoform 2 Intracellular Ca
2? leak CPVT (ARVC2 ?)
Intracellular Ca
2? release Contractile dysfunction Missense mutations
HF, SSS, AVND
Contractile activation in systole Pro-arrhythmogenic Deletion mutation
ATP2A2 SERCA2a pump Loss-of-function Darier disease
Intracellular SR Ca
2? uptake Depressed SR Ca
2? uptake
Muscle relaxation in diastole Depressed contraction and
relaxation
PLN Phospholamban Gain-of-function Dilated
cardiomyopathy,
early onset
Constitutive inhibition of
SERCA2a pump function
Increase in ratio of
PLN:SERCA2a results in
decreased SERCA2a
function
Missense and
deletion
mutations
PKA and/or CaMKII
phosphorylation of PNL
increases SR Ca
2? uptake
and contractile function
PLN hypophosphorylation
is associated with
decreased SR Ca
2?
uptake and contractile
dysfunction
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123myocardial infarction [27], mice with muscle LIM protein
knockout [28], mice with replication-restricted full-length
Coxsackievirus B3 overexpression and myocarditis [29],
and mice overexpressing either the catalytic protein kinase
A (PKA)-Ca subunit [30] or the cytosolic CaMKIIdc splice
variant [31]. Thus, different HF models appear to agree that
qualitatively similar changes of the intracellular Ca
2?
transient and subsequent alterations of EC coupling and
contractile dysfunction occur.
Local intracellular calcium abnormalities in heart
failure
While cardiac contraction and relaxation cycles are con-
trolled by a cell-wide (global) signaling event, the Ca
2?
transient, intracellular Ca
2? release occurs within local
(subcellular) Ca
2? release units as evidenced by elemen-
tary Ca
2? release events measured with bright ﬂuorescent
polycarboxylate dyes [8, 32]. How do local, elementary
Ca
2? release events, known as Ca
2? sparks, modulate the
intracellular Ca
2? transient? At a diastolic [Ca
2?]i of
approximately 100 nM, Ca
2? sparks occur at a very low
rate (100 s
-1 cell
-1). When the AP occurs, Ca
2? inﬂux
causes a large increase in cytosolic [Ca
2?]i within the tight
junctional subspace (Fig. 1a). A raise of junctional [Ca
2?]i
above nanomolar concentrations increases the spark rate
10
3 to 10
6 fold. Therefore, the ICa inﬂux current becomes
ampliﬁed by a dramatic increase in Ca
2? spark rate during
CICR. This implies that modulation of the Ca
2? spark rate
may control the Ca
2? transient amplitude and cardiac force
development (inotropy). Indeed, imaging experiments of
subcellular Ca
2? signaling have provided evidence that b-
adrenergic stimulation increases local Ca
2? release possi-
bly due to RyR2 phosphorylation [33].
An important advance why changes in the intracellular
Ca
2? transient occur in HF come from combined voltage-
clamp and Ca
2? spark imaging experiments to assess if
changes in EC coupling are responsible for depressed car-
diac function. A rat model of hypertension induced HF with
preserved Ca
2? inﬂux current (ICa) density showed that the
ability of any given ICa to activate SR Ca
2? sparks
(D[Ca
2?]i) was signiﬁcantly decreased [24]. Thus, HF is
accompanied by a decrease in the gain of EC coupling
(D[Ca
2?]i/ICa) which has been conﬁrmed in rats with myo-
cardial infarction [27], dogs with pacing-induced HF [34],
mice with viral myocarditis [29], and muscle LIM protein
knockout mice [35]. Additionally, structural changes of the
T-tubules, SR storage organelles, and/or the architecture of
the junctional microdomain cleft are all likely contributors
to defective EC coupling by altering the geometry of the
Ca
2? release unit potentially resulting in orphaned RyR2
release channels and/or abnormal CICR [36, 37].
Abnormal calcium release triggers fatal arrhythmias
Sudden unexpected death accounts for up to 50% of all
deaths in HF patients and is most often due to ventricular
tachyarrhythmias [38]. Both reentry and focal mechanisms
have been documented in patients with ischemic cardio-
myopathy [39]. At the cellular level, arrhythmias have been
associated with Ca
2? induced electrical abnormalities
including SR Ca
2? overload leading to intracellular Ca
2?
waves and Ca
2? activated transient inward current (ITI)
[40–42]. In digitalis treated cells, ITI was shown to initiate
delayed after depolarizations (DADs) [43]. Association of
SR Ca
2? leak with activation of a depolarizing Na
?/Ca
2?
exchange current is a likely mechanism of arrhythmogenic
ITI in HF [44–46].
Genetic linkage and translational studies have signiﬁ-
cantly advanced our understanding about speciﬁc Ca
2?
dependent arrhythmia mechanisms (Table 1). For instance,
RyR2 missense mutations may cause stress-induced syn-
cope and sudden death in a syndrome called Catecholam-
inergic Polymorphic Ventricular Tachycardia (CPVT) [47,
48]. Consistent with a b-AR and cAMP mediated stress
mechanism, PKA phosphorylated RyR2 channels contain-
ing CPVT mutations showed a signiﬁcant gain-of-function
defect and a Ca
2? leak mediated arrhythmia trigger
mechanism [49, 50]. Indeed, cardiomyocytes from knockin
mice with the RyR2-R2474S mutation identiﬁed earlier in
CPVT patients [47] showed Ca
2? leak mediated ITI cur-
rents and DADs during stimulation with catecholamines
(Fig. 1b) [51]. While we have to anticipate additional
mechanisms of Ca
2? leak in HF, mechanistic linkage of
CPVT mutant RyR2 dependent Ca
2? leak to arrhythmia
initiation [51] provides a speciﬁc mechanism of Ca
2?
dependent arrhythmia initiation which can be targeted and
tested by a novel class of RyR2 stabilizing compounds [51]
(Table 2).
Storage organelle and calcium transport dysfunction
Ca
2? is the central intracellular messenger which links an
incoming action potential to myoﬁlament activation and
cardiac contraction. Apart from EC coupling, [Ca
2?]i is
subject to physiological stress adaptation and a higher
systolic D[Ca
2?]i increases force development and cardiac
output (inotropy) [33]. Following the realization that SR
Ca
2? uptake might be depressed in failing cardiomyocytes,
the intracellular storage organelles and SR Ca
2? content
became a focus of intense research interest.
HF has been associated with decreased function of dif-
ferent Ca
2? transport mechanisms (Table 1) including the
sarcoendoplasmic reticulum (SR) Ca
2? ATPase (SERCA2)
[52, 53] and with increased function of the Na
?/Ca
2?
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123exchanger (NCX) [54]. The ratio of PLN:SERCA2 is a
critical determinant of cardiac Ca
2? homeostasis, and
increases in this ratio have been suggested to contribute to
increased diastolic Ca
2? levels and cardiac dysfunction
[53, 55, 56]. On the other hand, due to the changes in the
relative expression and function of NCX and SERCA2, a
net shift toward increased Ca
2? extrusion to the extracel-
lular space and a net decrease in SR Ca
2? uptake occurs
(Fig. 1c). Therefore, intracellular Ca
2? stores may develop
a relatively Ca
2? depleted state which has been conﬁrmed
experimentally in cardiomyocytes from dogs and humans
with HF [26, 34]. Decreased SR Ca
2? load may result in a
decreased amplitude and slower upstroke of the intracel-
lular Ca
2? transient. Since D[Ca
2?]i is an important
mediator of cardiac force development, a decreased
D[Ca
2?]i due to decreased SR load may result in decreased
force development. However, SR Ca
2? store depletion in
HF does not necessarily prevent an increase in Ca
2? spark
frequency [31] likely due to chronically increased RyR2
phosphorylation [57] and consistent with an increased
propensity for Ca
2? induced arrhythmias in HF.
Molecular mechanisms of depressed SR calcium uptake
Decreased SERCA2 function has been associated with
changes in the regulatory subunit PLN (Fig. 1c). PLN is a
phosphoprotein which inhibits SERCA2 in its dephospho-
rylated state, while phosphorylation of PLN during b-AR
stimulation relieves this inhibitory effect. The regulatory
role of PLN in myocardial contractility has been estab-
lished through the generation and characterization of
genetically altered mouse models, which revealed a cor-
relation between PLN expression and contractile function
[58–60]. PLN phosphorylation in HF is chronically
decreased (PLN hypophosphorylation) which may directly
contribute to depressed SR Ca
2? uptake [61]. Chronic PLN
hypophosphorylation can be predicted to compromise
cardiac stress adaptation mediated by cAMP and PKA.
Overexpression of the cardiac SERCA2a isoform or the
constitutively PKA phosphorylated PLN-Ser
16 improved
function in rats following aortic banding-induced HF [62]
and decreased arrhythmia susceptibility following ische-
mia-reperfusion cardiomyopathy in pigs [63].
Phospholamban is potently inhibited by phosphatase 1
(PP1), which in turn is inhibited by phosphatase inhibitor I-
1 following PKA phosphorylation and I-1 activation.
Consistent with this mechanism, overexpression of an
activated I-1 form in mice protects the animals from HF
development [64]. Moreover, the identiﬁcation of PLN
mutations in patients with dilated cardiomyopathy has
strengthened its critical role in cardiac function. Thus,
inhibition of PLN activity and restoration of SR Ca
2?
cycling were suggested to hold promise for treating heart
failure [65].
Molecular mechanisms of intracellular calcium leak
In samples from patients and animals with HF, RyR2 is
chronically PKA hyperphosphorylated contributing to
intracellular Ca
2? leak and remodeling of the macromo-
lecular channel complex [7, 66, 67]. If the hyperadrenergic
state in HF leads to secondary downregulation of b-adren-
ergic signaling and globally reduced intracellular cAMP
synthesis, which molecular mechanism maintains RyR2
PKA hyperphosphorylation and intracellular Ca
2? leak?
During HF, phosphatases (PP1 and PP2A) are depleted
from the RyR2 complex which may contribute to a reduced
rate of RyR2 dephosphorylation [61, 66]. In human HF, the
cAMP-speciﬁc phosphodiesterase isoform PDE4D3 was
found to be decreased in the RyR2 complex paralleled by a
decrease in cAMP hydrolyzing activity [57]. Thus, PKA
hyperphosphorylation and calstabin2 depletion may both
Table 2 Clinical and novel
drug rationales to treat HF
OTA off-target activity, n/a not
available
Target Drug Advantage Disadvantage
NCX transporter
Forward mode SEA0400 Reduced infarct size OTA
Reverse mode SEA0400, KB-R7943 n/a Negative inotropic?
RyR2 channel
Phosphorylation b-Blockers Survival, progression Indirect mechanism
ACE inhibitors Survival, progression Indirect mechanism
Pore block Tetracaine n/a OTA; n/a
Stabilization JTV519 Speciﬁcity OTA
S107 Speciﬁcity n/a
SERCA2 pump
Stimulation Gingerol Speciﬁcity Toxicity; n/a
Overexpression AAV-SERCA2a Speciﬁcity Gene therapy
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123contribute to chronic RyR2 activation and intracellular
Ca
2? leak (Fig. 1c). Indeed, single RyR2 channels from
human failing hearts showed an increased open probability
consistent with intracellular Ca
2? leak [66].
Using site-directed mutagenesis of RyR2, a speciﬁc
Ca
2?/calmodulin-dependent protein kinase II (CaMKII)
phosphorylation site (Ser
2814) distinct from the PKA
phosphorylation site (Ser
2808) has been identiﬁed [6].
CaMKII phosphorylation increased RyR2 Ca
2? sensitivity
and open probability. Since CaMKII was activated by
higher cardiac pacing rates, RyR2 CaMKII phosphoryla-
tion may contribute to enhanced CICR and enhanced
contractility at higher heart rates. However, the rate-
dependent increase in RyR2 phosphorylation by CaMKII
as seen in sham-operated, healthy rat hearts was compro-
mised in rat hearts with HF [6]. Transgenic mice over-
expressing the cytosolic CaMKIIdc isoform develop
cardiac hypertrophy, HF, and intracellular Ca
2? leak [68].
Acute overexpression of CaMKIIdc in cardiomyocytes
resulted in signiﬁcant SR Ca
2? leak without changes in
contractile function [69]. Adenoviral CaMKII overexpres-
sion was not associated with calstabin2 dissociation from
RyR2 [69] conﬁrming earlier results [6]. On the other hand,
PKA phosphorylation of RyR2 resulted in depletion of the
stabilizing calstabin2 subunit [6], and decreased calstabin2
levels have been linked to Ca
2? triggered arrhythmias in
the structurally normal heart [49]. Disruption of RyR2
PKA phosphorylation in Ser2808Ala knockin mice with
myocardial infarct induced HF has provided evidence that
PKA hyperphosphorylation induced SR Ca
2? leak may
directly contribute to HF progression [70]. However, the
signiﬁcance of concomitant PKA and/or CaMKII RyR2
phosphorylation in Ca
2? dysregulation during HF has not
been addressed conclusively.
Altered sodium handling in heart failure
Intracellular Na
? and Ca
2? concentrations are intricately
coupled through the NCX current. In addition, Na
? inﬂux
through sarcolemmal NaV1.5 channels contributes to
intracellular [Na
?]i homeostasis (Fig. 1a). Studies about
[Na
?]i in human myocardium showed a stimulation rate
dependent increase in [Na
?]i [71, 72]. For any given stim-
ulation rate, human end-stage failing myocardium showed a
shift toward higher intracellular [Na
?]i [71]. In a rabbit HF
model with elevated [Na
?]i, the function of the Na
?/K
?-
ATPase function was found normal [73]. A potential role of
altered Na
? channel inactivation and a signiﬁcantly
increased late INa,L in HF as a cause of intracellular [Na
?]i
overload has been documented in animal models of HF and
human failing myocardium [74, 75]. Slow pacing of failing
cardiomyocytes with increased [Na
?]i may enhance Ca
2?
inﬂux from the extracellular side through reverse mode
NCX contributing to increased SR Ca
2? load and force
development. Indeed, at higher pacing rates failing cardio-
myocytes with high [Na
?]i are prone to diastolic Ca
2?
overload and contractile dysfunction. Interestingly, phar-
macological inhibition of INa,L was found to improve dia-
stolic dysfunction in failing human myocardium [76].
Additionally, increased late INa,L may result in Ca
2?
induced electrical cardiomyocyte dysfunction as shown in
SCN5A-DKPQ knockin mice resembling the Long-QT3
syndrome [77].
Altered force frequency relation in the failing human
heart
Pathophysiological consequences of altered EC coupling
have an immediate impact on cardiac stress adaptation dur-
inghigherheartrates.Theforce–frequencyrelation(FFR)or
staircase phenomenon of healthy human myocardium and
within physiological limits describes a heart rate dependent
increase in contractile force and cardiac output. However, in
failing human hearts or isolated muscle preparations, the
frequency-dependent potentiation of contractile force is
blunted or, even worse, inversed [78]. Alteration of the FFR
in the failing human heart has been accepted as a functional
milestone which may partially explain the decreased exer-
cise capacity of symptomatic HF patients.
Using aequorin Ca
2? measurements it has been shown
that a positive FFR in normal healthy myocardium is
associated with a positive D[Ca
2?]i transient amplitude–
frequency relation, and vice versa, a negative FFR in the
failing myocardium is associated with an inverted
D[Ca
2?]i–frequency relation [18]. Alterations of the fre-
quency response of contractile performance have been
conﬁrmed in vivo in HF patients [79]. A different experi-
mental protocol which is thought to enable increased Ca
2?
accumulation into the SR stores in diastole, uses post-rest
pacing which typically produces an increase in developed
force in healthy myocardium also referred to as ‘post-rest
potentiation’. However, alterations in post-rest potentiation
that may underlie reduced stress adaptation and the FFR
inversion have been associated with a blunted post-rest
D[Ca
2?]i increase of SR Ca
2? content (Fig. 2)[ 80]. While
in healthy human myocardium a pronounced upregulation
of SR Ca
2? content occurs at higher heart rates, failing
human myocardium shows a blunted regulation of SR Ca
2?
content [26]. Therefore, the chronic hyperadrenergic state
and associated higher heart rates in HF patients may create
an increased risk for Ca
2? induced cardiac dysfunction and
arrhythmias. Accordingly, novel therapeutic strategies have
successfully used pharmacological heart rate reduction in
HF patients to improve prognostic outcome [81].
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Several therapeutic rationales exist which aim to correct
known molecular Ca
2? signaling abnormalities in HF as
summarized in Table 2. Among these strategies, NCX
blockers may have therapeutic utility if mode-selective
block can be established and/or risks for disturbing intra-
cellular Ca
2? metabolism can be avoided. Partial inhibition
of NCX by SEA-0400 in MLP
-/-knockout cardiomyocytes
with heart failure showed a net gain of [Ca
2?]i and SR load
but no improvement in contractility whereas cardiomyo-
cytes from mice with aortic-banding induced hypertrophy
and HF showed improved contractile function [82]. Further
development of NCX blockers for HF will depend on the
critical assessment of the potential beneﬁts of NCX reduc-
tion versus effects on [Ca
2?]i by reﬁning mode dependence
and/or including additional targeting strategies.
Some traditional ion channel blockers like tetracaine
inhibit ion permeation through RyR2 channels, however,
lack of speciﬁcity and potential side effects on contractile
function indicate signiﬁcant limitations toward therapeutic
applicability [83, 84]. Recently, the efﬁcacy of novel RyR2
channel stabilizing drugs of the 1,4-benzothiazepine class
(JTV519 or K201) which stabilize the RyR2 closed state
but do not block ion permeation has been established in
animal models of heart failure where they inhibit pro-
gression of cardiac remodeling and dysfunction [57, 85,
86]. RyR2 stabilizing compounds with high speciﬁcity and
cardiac activity have been developed [51] and their efﬁcacy
as potential HF treatment is under investigation. Addi-
tionally, b-blockers and angiotensin-II receptor blockers
have been associated with beneﬁcial effects on RyR2
channel dysfunction in HF through mechanisms which
indirectly prevent excess post-translational modiﬁcation of
RyR2, e.g. by PKA hyperphosphorylation or nitrosylation
[87–89].
Adeno-associated viruses (AAVs) are currently best
suited for myocardial gene delivery due to minimal path-
ogenicity and several serotypes exhibit tropism for the
heart. Following identiﬁcation and comprehensive charac-
terization of SERCA2a as a potential therapeutic target in
HF, cardiac gene therapy trials using replication-deﬁcient
viral vectors (AAV-SERCA2a) have been approved by the
US Food and Drug Administration and are under review
with the UK regulatory authorities for clinical trials [90].
Fig. 2 Representative traces of aequorin-based Ca
2? signals and
corresponding isometric forces from human nonfailing (top) and
failing (bottom) myocardial muscle preparations. Upper panel:
Nonfailing myocardium shows post-rest potentiation of the intracel-
lular Ca
2? transient and force development which increases from 10
to 120 s rest period. Lower panel: Failing myocardium shows
depressed post-rest intracellular Ca
2? transient and force develop-
ment after 120 s rest. Steady-state pre-rest signals are shown on the
left of each trace; ﬁrst and second post-rest signals are shown
afterwards; post-rest signals represent 10 s (left) and 120 s (right),
dimensions as indicated. Reproduced with permission from the
Journal of Clinical Investigation (Pieske et al. [80])
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123Summary and future perspectives
HF is characterized by chronic maladaptive changes and a
poor prognosis. Chronic activation of intracellular signaling
pathwaysmediatesstructuralandfunctionalremodelingofthe
failingheart.Changes inECcouplingatthe level oflocal and
globalCa
2? signals represent a key mechanism of contractile
depression and arrhythmia propensity. It has become
increasinglyclearthatcardiacremodelinginHFoccurswithin
cytosolic Ca
2? signaling microdomains. Translational
approaches about the local and global Ca
2? signaling mech-
anisms, remodeling mechanisms, and related disease pro-
cesseswillbeofkeyimportancetodevelopnovelandspeciﬁc
therapeutic rationales. We anticipate that Ca
2? imaging
techniqueswillsigniﬁcantlyincreaseourunderstandingofthe
cardiac pathophysiology underlying HF and boost develop-
ment of novel therapeutic strategies in the future.
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